MaxCyte, Inc. Notice of Full Year Results (0875Y)

TIDMMXCT

RNS Number : 0875Y

MaxCyte, Inc.

01 March 2017

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Full Year Results

Maryland, USA - 1 March 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, will be announcing its full year audited results for the year ended 31 December 2016 on Monday 20 March 2017.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11.00am GMT on the day of the results at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG.

For further information please contact:

 
 MaxCyte                                [phone] 
 Doug Doerfler, Chief Executive 
  Officer 
  Ron Holtz, Chief Financial 
  Officer 
 
 Nominated Adviser and Broker 
  Panmure Gordon 
  Freddy Crossley (Corporate 
  Finance) 
  Fabien Holler 
  Duncan Monteith 
  Tom Salvesen (Corporate Broking)      [phone] 
 Financial PR Adviser                   [phone] 
  Consilium Strategic Communications     [e-mail] 
 Mary-Jane Elliott 
  Chris Welsh 
  Lindsey Neville 
 

About MaxCyte

MaxCyte (LSE: MXCT), is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve development and commercialization challenges. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade high-performance cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines.

MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information, visit http://www.maxcyte.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORTPMJTMBJTBIR

(END) Dow Jones Newswires

March 01, 2017 02:01 ET (07:01 GMT)